A Comissão Europeia (CE) aprovou a comercialização da versão de 50 miligramas de administração semanal do fármaco Enbrel (etanercept), da Wyeth, como alternativa à actual versão de 25 miligramas, administrada duas vezes por semana, para pacientes com psoríase em placas moderada a grave.
Arquivo
- Belimumab is well tolerated and depletes B cells effectively in patients with SLE
- Are classification criteria for vasculitis useful in clinical practice?
- Antiphospholipid (Hughes) syndrome: beyond pregnancy morbidity and thrombosis
- Infections and vasculitis
- British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years)
- Environmental factors and autoimmune thyroiditis
- Advances in the use of biologic agents for the treatment of systemic vasculitis
- Molecular effects of exercise in patients with inflammatory rheumatic disease
- Enbrel aprovado na Europa para a psoríase infantil
- Certolizumab pegol
- Algorithm that predicts progression of undifferentiated arthritis has been validated
- Transcription profiling of rheumatic diseases
- Stanford Develops Imaging Technique To Catch Arthritis Early In Onset
- Potential New Antibody Treatment For Autoimmune Diseases Discovered By Scientists At UCSF
- Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinerAIR-Sclerodermie study
- Current And Emerging Therapies Have No Advantage Over Enbrel In Reducing The Signs And Symptoms Of Rheumatoid Arthritis
- Adverse effects of low-dose glucocorticoids and DMARD therapy in patients with RA—a complex relationship?
- Novel anti-CD20 monoclonal antibody shows promise as therapy for RA
- Body composition correlates with physical function in patients with RA
- Developments in the clinical understanding of rheumatoid arthritis
- Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort
- What is the optimal treatment for patients with RA who fail to respond to monotherapy with methotrexate?
- Discovery Of Process Found To Play Role In Rheumatoid Arthritis Could Lead To New Treatment
- Efficacy and safety of anti-TNF therapy for ankylosing spondylitis: long-term results
- There’s more to life than everyday function: the challenge of measuring social role participation in ankylosing spondylitis
- How regulatory T cells work
- Primary prevention of systemic lupus erythematosus
- Infliximab therapy for patients with ankylosing spondylitis: on-demand or continuous treatment?
- The molecular basis of pain and its clinical implications in rheumatology
- Adalimumab suppresses markers of structural damage in ankylosing spondylitis
- Available therapeutic options following failure of a first anti-TNF agent
- New NICE Guidelines To Help Thousands Of People With Rheumatoid Arthritis
- NICE guidelines on anti-tumor necrosis factor therapy for RA